Entyvio may improve disease course in patients with immune-mediated diarrhea colitis

Entyvio therapy may improve disease course of immune-mediated diarrhea colitis and decrease steroid exposure, according to a presentation at the American College of Gastroenterology virtual annual meeting.”“Our conclusions [show] compared to infliximab, long-term use of vedolizumab has equal efficacy in clinical remission, slight delay to symptom response, better IMDC disease course, lower IMDC recurrence, less cancer progression and better survival rate over 40 months,” Yinghong Wang, MD, PhD, assistant professor at The University of Texas MD Anderson Cancer Center, saidRead More

Share on facebook
Share on twitter
Share on linkedin